ELVN Insider Trading Activity and SEC Form 4 Filings
ELVN insider trading summary
Over the past 12 months, insiders at Enliven Therapeutics, Inc. (ELVN) reported 86 sales worth $178.7M by 12 insiders and no open-market purchases on SEC Form 4. Net insider selling was $178.7M.
Latest ELVN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 19, 2026 | Helen Louise Collins | Chief Medical Officer | Sell | $192K (5,000 @ $38.47) |
| Oct 19, 2026 | Benjamin Hohl | Chief Financial Officer | Sell | $232K (6,018 @ $38.48) |
| Oct 1, 2026 | J. Scott Garland | Insider | Sell | $607K (13,000 @ $46.67) |
| Sep 17, 2026 | Benjamin Hohl | Chief Financial Officer | Sell | $177K (3,535 @ $50.03) |
| Sep 17, 2026 | Helen Louise Collins | Chief Medical Officer | Sell | $94K (1,844 @ $50.71) |
| Sep 17, 2026 | Helen Louise Collins | Chief Medical Officer | Sell | $12K (240 @ $51.48) |
| Sep 17, 2026 | Benjamin Hohl | Chief Financial Officer | Sell | $111K (2,194 @ $50.72) |
| Sep 17, 2026 | Helen Louise Collins | Chief Medical Officer | Sell | $146K (2,916 @ $50.03) |
| Sep 17, 2026 | Benjamin Hohl | Chief Financial Officer | Sell | $15K (289 @ $51.49) |
| Aug 17, 2026 | Benjamin Hohl | Chief Financial Officer | Sell | $270K (4,630 @ $58.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.